Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval

Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval

NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen...

menu
menu